Autoinmunidad e Inmunodeficiencias
CTS150
Hospital Universitario de la Princesa
Madrid, EspañaPublicaciones en colaboración con investigadores/as de Hospital Universitario de la Princesa (13)
2024
-
Efficacy and safety of a structured de-escalation from antipseudomonal β-lactams in bloodstream infections due to Enterobacterales (SIMPLIFY): an open-label, multicentre, randomised trial
The Lancet Infectious Diseases, Vol. 24, Núm. 4, pp. 375-385
2016
-
Comprehensive clinical and epidemiological assessment of colonisation and infection due to carbapenemase-producing Enterobacteriaceae in Spain
Journal of Infection, Vol. 72, Núm. 2, pp. 152-160
-
Sarcoidosis: an update on current pharmacotherapy options and future directions
Expert Opinion on Pharmacotherapy, Vol. 17, Núm. 18, pp. 2431-2448
2015
-
Efficacy of and risk of bleeding during pegylated interferon plus ribavirin treatment in HIV/HCV-coinfected patients with pretreatment thrombocytopenia
European Journal of Clinical Microbiology and Infectious Diseases, Vol. 34, Núm. 9, pp. 1879-1884
2013
-
Benefits from sustained virologic response to pegylated interferon plus ribavirin in HIV/hepatitis C virus-coinfected patients with compensated cirrhosis
Clinical Infectious Diseases, Vol. 56, Núm. 11, pp. 1646-1653
-
Short communication: Atazanavir-based therapy is associated with higher hepatitis C viral load in HIV type 1-infected subjects with untreated hepatitis C
AIDS Research and Human Retroviruses, Vol. 29, Núm. 2, pp. 223-225
2012
-
Hepatitis C virus genotype 4 responds better to pegylated interferon with ribavirin than genotype 1 in HIV-infected patients
AIDS, Vol. 26, Núm. 13, pp. 1721-1724
-
Response to pegylated interferon plus ribavirin among HIV/hepatitis C virus-coinfected patients with compensated liver cirrhosis
Clinical Infectious Diseases, Vol. 55, Núm. 12, pp. 1719-1726
-
The undiagnosed cases of Clostridium difficile infection in a whole nation: Where is the problem?
Clinical Microbiology and Infection, Vol. 18, Núm. 7
2008
2007
-
Influence of concomitant antiretroviral therapy on the rate of sustained virological response to pegylated interferon plus ribavirin in hepatitis C virus/HIV-coinfected patients
Journal of Antimicrobial Chemotherapy, Vol. 60, Núm. 6, pp. 1347-1354
-
Rapid virological response at week 4 predicts response to pegylated interferon plus ribavirin among HIV/HCV-coinfected patients
Antiviral Therapy, Vol. 12, Núm. 4, pp. 523-529
2006
-
Antiretroviral therapy based on protease inhibitors as a protective factor against liver fibrosis progression in patients with chronic hepatitis C
Antiviral Therapy, Vol. 11, Núm. 7, pp. 839-846